Indegene reports strong growth, AI-led future for FY 2024-25

Indegene Limited reported a strong financial year for FY 2024-25, with revenue from operations reaching ₹28,393 million, a 9.6% year-over-year increase. Profit after tax (PAT) grew by 20.8% to ₹4,067 million, and EBITDA stood at ₹5,622 million, up 5.0%. The company declared a final dividend of ₹2 per equity share.

The company highlighted significant progress in its AI-first approach, with its proprietary GenAI platform, Cortex, driving rapid innovation and value delivery in life sciences. Indegene’s services, spanning commercial, medical, regulatory, and safety functions, have embedded AI, machine learning, and natural language processing to enhance efficiency and accuracy. Key achievements include a 32% increase in efficiency and 95% accuracy in GenAI-simplified SRD content extraction.

Indegene anticipates cautious but moderate growth in 2025, driven by new product launches in the biopharma sector. The company plans to continue expanding its footprint and deepening client relationships, with a focus on profitable growth and innovation.